Wednesday, February 10, 2010, 4:32am EST - Canadian Markets open in 4 hours and 58 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Theravance Inc. (THRX)

 On Feb 9: 10.21 USD   0.00 (0.00%)  
MORE ON THRX
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Theravance, Inc. (NGM:THRX) Delayed quote dataEdit
Last Trade: 10.21 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 10.21
Open: N/A
Bid: N/A
Ask: N/A
1y Target Est: 17.29
Day's Range: N/A - N/A
52wk Range: 9.65 - 18.56
Volume: 0
Avg Vol (3m): 328,659
Market Cap: 648.97M
P/E (ttm): N/A
EPS (ttm): -1.26
Div & Yield: N/A (N/A%)
Theravance Inc. (THRX)
1d  5d  3m  6m  1y  2y  5y  max 
 Add THRX to Portfolio   Download Data

HEADLINES
• Theravance to Report Fourth Quarter and Full Year 2009 Financial Results on February 11, 2010
Marketwire (Wed, Feb 3)
• Theravance Announces New Employment Inducement Awards
Marketwire (Mon, Feb 1)
• AstraZeneca to Ax 8,000 More Workers: Biotech's Latest Mishaps
at Seeking Alpha (Sun, Jan 31)
• FDA seeks more data for Theravance drug
AP (Thu, Jan 28)
• FDA tells Theravance its telavancin response is incomplete
at bizjournals.com (Thu, Jan 28)
• UPDATE - FDA deems Theravance response on Telavancin incomplete
at Reuters (Thu, Jan 28)
• THERAVANCE INC Files SEC form 8-K, Other Events
EDGAR Online (Thu, Jan 28)
• Theravance Announces Receipt of Additional FDA Communication Regarding Telavancin NDA for the Treatment of Nosocomial Pneumonia
Marketwire (Thu, Jan 28)
• Industry Expert Identifies "Companion Diagnostics" Testing As New High Growth Sector In Health Care Services: KRAS Mutation Testing As Predictive Biomarker For EGFR Inhibitors Is First Wave
Wall Street Transcript (Wed, Jan 27)
• THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online (Wed, Jan 20)
• THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online (Thu, Jan 14)
More Headlines for THRX...
ANALYST
EPS Est (next year) (Dec-09) : -1.32
EPS Est (in 2 years) (Dec-10) : -1.13
Avg Rec (current)*: 2.6
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines across various therapeutic areas, including respiratory disease, bacterial infections, and gastrointestinal mot...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices